Pharmacological Treatment of Vascular Dementia: A Molecular Mechanism Perspective

Huang Kuang1, Zhi-Feng Zhou1, Yu-Ge Zhu1

  • 11Department of Physiology, College of Medicine, Nanchang University, Nanchang, China.

Aging and Disease
|February 3, 2021
PubMed

Insights

Vascular dementia (VaD) is a common neurodegenerative disease with no standard treatments. This review explores current pharmacological options and molecular mechanisms, suggesting combination therapies may be key for future vascular dementia management.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Vascular dementia (VaD) is the second leading cause of dementia in older adults, characterized by cognitive decline due to cerebrovascular issues.
  • The exact causes of VaD remain unclear, hindering effective treatment development.
  • Current treatments offer only symptomatic relief and do not halt disease progression.

Purpose of the Study:

  • To review the current state of pharmacological treatments for VaD.
  • To examine treatments in relation to key molecular mechanisms of VaD pathogenesis.
  • To identify potential future therapeutic strategies for VaD.

Main Methods:

  • Literature review of current research on VaD pharmacological treatments.
  • Analysis of studies focusing on molecular mechanisms: oxidative stress, cholinergic system, neuroinflammation, apoptosis, and synaptic plasticity.
  • Synthesis of findings to evaluate treatment efficacy and future directions.

Main Results:

  • No approved standard treatments currently exist for VaD.
  • Existing drugs provide only symptomatic relief.
  • Understanding molecular pathways offers targets for novel therapeutic approaches.

Conclusions:

  • Pharmacological treatments for VaD are limited and primarily symptomatic.
  • Targeting multiple molecular mechanisms, such as oxidative stress and neuroinflammation, is a promising avenue.
  • Combined therapeutic strategies hold potential for future VaD management.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
581
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
756
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
285
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
322
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
96